RxDoctor Payments Data

Peter Chang, MD

Family Medicine · San Angelo, TXNPI 1780688028

Payments from drug & device makers

$20,212in general payments, 2019–2025

Across 428 payments — averaging $47.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$15K
  • Novo Nordisk$933
  • AstraZeneca$683
  • Lilly USA, LLC$441
  • Ardelyx, Inc.$388
  • Johnson & Johnson$295
  • plus $2K from 38 others

What the payments were for

  • Consulting fees$13,50067%
  • Food & beverage$6,68533%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,212 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$229,509
Medicare patients
346
Services billed
5,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide146$181,832
OzempicSemaglutide103$131,066
EliquisApixaban220$97,886
LinzessLinaclotide94$64,362
JanuviaSitagliptin Phosphate143$50,492
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$49,668
MyrbetriqMirabegron149$44,177
VraylarCariprazine Hcl22$33,709
JardianceEmpagliflozin84$33,039
WegovySemaglutide16$21,877
Breo ElliptaFluticasone/Vilanterol38$20,447
XareltoRivaroxaban29$19,944
UbrelvyUbrogepant17$19,199
KeppraLevetiracetam12$18,035
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,033$17,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$441$198,149165 claims
Novo NordiskOzempic, Wegovy$933$152,943119 claims
AbbVieLinzess, Vraylar, Ubrelvy$15,294$117,270133 claims
PfizerEliquis$88$97,886220 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Spiriva Respimat$103$74,997141 claims
GSKTrelegy Ellipta, Breo Ellipta$203$70,116101 claims
MerckJanuvia, Belsomra$31$56,532157 claims
Astellas Pharma US IncMyrbetriq$12$44,177149 claims
Johnson & JohnsonXarelto$295$19,94429 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Motegrity$169$17,73132 claims
NovartisEntresto$73$10,21650 claims
AstraZenecaBreztri Aerosphere$683$9,06014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →